Genoa Ventures is an early-stage venture capital firm founded in 2018 by Jenny Rooke, Ph.D. See contact routes.
Genoa Ventures is an early-stage venture capital firm founded in 2018 by Jenny Rooke, Ph.D., that invests at the convergence of biology and technology. The firm targets pre-seed to Series A companies in sectors including synthetic biology, molecular diagnostics, research tools, agriculture, and industrial biology, primarily within the US with some activity in Europe. Typical check sizes range from $500,000 to $5 million, and Genoa often leads rounds while providing strategic guidance alongside capital. Notable portfolio companies include Ionpath, BRAINBox Solutions, and Intabio, which was acquired by SCIEX in 2021. Genoa distinguishes itself through a “bioconvergence” thesis, emphasizing science-driven startups that blend biology, technology, and data science to transform industries. The firm manages over $150 million in assets under management as of 2023 and is currently investing from its third fund.
StartupFundraising tracks this firm record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to comparable investors.
Investors like Genoa Ventures · Full investor directory · Investor access · Company funding database